Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-4-19
pubmed:abstractText
We previously demonstrated that the Kampo formula chotosan (CTS) ameliorated spatial cognitive impairment via central cholinergic systems in a chronic cerebral hypoperfusion (P2VO) mouse model. In this study, the object discrimination tasks were used to determine if the ameliorative effects of CTS on P2VO-induced cognitive deficits are a characteristic pharmacological profile of this formula, with the aim of clarifying the mechanisms by which CTS enhances central cholinergic function in P2VO mice. The cholinesterase inhibitor tacrine (THA) and Kampo formula saikokeishito (SKT) were used as controls. P2VO impaired object discrimination performance in the object recognition, location, and context tests. Daily administration of CTS (750 mg/kg, p.o.) and THA (2.5 mg/kg, i.p.) improved the object discrimination deficits, whereas SKT (750 mg/kg, p.o.) did not. In ex vivo assays, tacrine but not CTS or SKT inhibited cortical cholinesterase activity. P2VO reduced the mRNA expression of m(3) and m(5) muscarinic receptors and choline acetyltransferase but not that of other muscarinic receptor subtypes in the cerebral cortex. Daily administration of CTS and THA but not SKT reversed these expression changes. These results suggest that CTS and THA improve P2VO-induced cognitive impairment by normalizing the deficit of central cholinergic systems and that the beneficial effect on P2VO-induced cognitive deficits is a distinctive pharmacological characteristic of CTS.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1347-8613
pubmed:author
pubmed:issnType
Print
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
360-73
pubmed:meshHeading
pubmed-meshheading:17409635-Acetylcholinesterase, pubmed-meshheading:17409635-Actins, pubmed-meshheading:17409635-Animals, pubmed-meshheading:17409635-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:17409635-Brain Ischemia, pubmed-meshheading:17409635-Cerebral Cortex, pubmed-meshheading:17409635-Cerebrovascular Circulation, pubmed-meshheading:17409635-Choline O-Acetyltransferase, pubmed-meshheading:17409635-Cholinergic Fibers, pubmed-meshheading:17409635-Cholinesterase Inhibitors, pubmed-meshheading:17409635-Chronic Disease, pubmed-meshheading:17409635-Cognition Disorders, pubmed-meshheading:17409635-Discrimination (Psychology), pubmed-meshheading:17409635-Drugs, Chinese Herbal, pubmed-meshheading:17409635-Exploratory Behavior, pubmed-meshheading:17409635-Male, pubmed-meshheading:17409635-Medicine, Kampo, pubmed-meshheading:17409635-Mice, pubmed-meshheading:17409635-Mice, Inbred ICR, pubmed-meshheading:17409635-RNA, Messenger, pubmed-meshheading:17409635-Receptors, Muscarinic, pubmed-meshheading:17409635-Recognition (Psychology), pubmed-meshheading:17409635-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17409635-Tacrine
pubmed:year
2007
pubmed:articleTitle
Chotosan, a kampo formula, ameliorates chronic cerebral hypoperfusion-induced deficits in object recognition behaviors and central cholinergic systems in mice.
pubmed:affiliation
Division of Medicinal Pharmacology, Institute of Natural Medicine, University of Toyama, Sugitani, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't